2. Search Result
Search Result
Results for "

target s/C AS R

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Peptides

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135045
    (S,R,S)-AHPC-C4-COOH

    VH032-C4-COOH

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C4-COOH (VH032-C4-COOH) (linker 45) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-targeted PROTAC .
    (S,R,S)-AHPC-C4-COOH
  • HY-130711C
    (S,R,S)-AHPC-C3-NH2 dihydrochloride

    VH032-C3-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C3-NH2 (dihydrochloride) is the dihydrochloride form of (S,R,S)-AHPC-C3-NH2 (HY-130711). (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .
    (S,R,S)-AHPC-C3-NH2 dihydrochloride
  • HY-114176
    (S,R,S)-AHPC-C4-NH2 hydrochloride

    VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligASe Ligand-Linker Conjugates 28

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .
    (S,R,S)-AHPC-C4-NH2 hydrochloride
  • HY-129941A
    (S,R,S)-AHPC-C10-NH2 dihydrochloride

    VH032-C10-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC .
    (S,R,S)-AHPC-C10-NH2 dihydrochloride
  • HY-129941
    (S,R,S)-AHPC-C10-NH2

    VH032-C10-NH2

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC .
    (S,R,S)-AHPC-C10-NH2
  • HY-114176B
    (S,R,S)-AHPC-C4-NH2 dihydrochloride

    VH032-C4-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .
    (S,R,S)-AHPC-C4-NH2 dihydrochloride
  • HY-114176A
    (S,R,S)-AHPC-C4-NH2

    VH032-C4-NH2

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .
    (S,R,S)-AHPC-C4-NH2
  • HY-147025
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
    1 Publications Verification

    		 PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia .
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
  • HY-148406
    (S,R,S)-AHPC-C10-NHBoc

    		E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C10-NHBoc is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC (HY-125845) based VHL ligand and a linker used for BET-Targeted PROTAC .
    (S,R,S)-AHPC-C10-NHBoc
  • HY-131866
    (S,R,S)-CO-C2-acid

    VH 032 amide-alkylC2-acid

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-CO-C2-acid (VH 032 amide-alkylC2-acid) is a functionalized von-Hippel-Lindau (VHL) protein ligand that can be used in PROTAC research and development. (S,R,S)-CO-C2-acid contains an E3 ligand alkyl ligand for conjugation of target protein ligands .
    (S,R,S)-CO-C2-acid
  • HY-130711
    (S,R,S)-AHPC-C3-NH2

    VH032-C3-NH2

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .
    (S,R,S)-AHPC-C3-NH2
  • HY-130711A
    (S,R,S)-AHPC-C3-NH2 TFA

    VH032-C3-NH2 TFA

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .
    (S,R,S)-AHPC-C3-NH2 TFA
  • HY-138678
    (R,S,S)-VH032

    		Ligands for E3 Ligase Cancer
    (R,S,S)-VH032 is Ligand for E3 Ligase used in the synthesis of PROTACs. VH032 is a VHL ligand and VHL/HIF-1α interaction inhibitor that recruits von Hippel-Lindau (VHL) proteins. (R,S,S)-VH032 synthesizes the tau-targeting small molecule PROTAC C004019 (HY-138669) .
    (R,S,S)-VH032
  • HY-151791
    (S,R,S)-AHPC-C6-PEG3-butyl-N3

    		ADC Linker Others
    (S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. (S,R,S)-AHPC-C6-PEG3-butyl-N3 serves as crosslinker-E3 ligase ligand conjugate, Click reactive protein degrader building block for PROTAC research, Template for synthesis of targeted protein degrader, VH032 conjugate . (S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    (S,R,S)-AHPC-C6-PEG3-butyl-N3
  • HY-157166
    EGFR kinase inhibitor 2

    		EGFR Cancer
    EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S mutants. EGFR kinase inhibitor 2 has the potential to address acquired resistance in the treatment of non-small cell lung cancer .
    EGFR kinase inhibitor 2
  • HY-109190
    Seralutinib
    1 Publications Verification

    GB002; PK10571

    		 PDGFR c-Fms c-Kit Cardiovascular Disease
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .
    Seralutinib
  • HY-P2548
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

    		EGFR Others
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated
  • HY-161275
    BI-4732

    		EGFR Cancer
    BI-4732 a potent inhibitor EGFR-activating (E19del and L858R) and T790M mutations, with high blood-brian barrier penetration, targeting a broad range of EGFR mutations, including C797S. BI-4732 has anti-tumor activity .
    BI-4732
  • HY-50905
    Dovitinib
    Maximum Cited Publications
    7 Publications Verification

    CHIR-258; TKI258

    		 FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Cancer
    Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
    Dovitinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: